These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 19285407

  • 1. Clinicopathologic correlates of giant pituitary adenomas.
    Chacko G, Chacko AG, Lombardero M, Mani S, Seshadri MS, Kovacs K, Scheithauer BW.
    J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review.
    Sahli R, Christ ER, Seiler R, Kappeler A, Vajtai I.
    Pathol Res Pract; 2006 May; 202(6):457-64. PubMed ID: 16497445
    [Abstract] [Full Text] [Related]

  • 3. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W, Lüdecke B, Lüdecke DK.
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [Abstract] [Full Text] [Related]

  • 4. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
    Rishi A, Sharma MC, Sarkar C, Jain D, Singh M, Mahapatra AK, Mehta VS, Das TK.
    Neurol India; 2010 Feb; 58(3):418-23. PubMed ID: 20644271
    [Abstract] [Full Text] [Related]

  • 5. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
    Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, Scheithauer BW.
    Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
    [Abstract] [Full Text] [Related]

  • 6. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients.
    Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M.
    Neurosurgery; 2007 Jun; 60(6):993-1002; discussion 1003-4. PubMed ID: 17538372
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
    Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Böcher-Schwarz HG, Hainfellner J, Knosp E.
    Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gender-related differences in non-functioning pituitary adenomas.
    Schaller B.
    Neuro Endocrinol Lett; 2003 Dec; 24(6):425-30. PubMed ID: 15073569
    [Abstract] [Full Text] [Related]

  • 11. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
    Wolfsberger S, Kitz K, Wunderer J, Czech T, Boecher-Schwarz HG, Hainfellner JA, Knosp E.
    Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
    [Abstract] [Full Text] [Related]

  • 12. Pituitary adenoma: a DNA flow cytometric study of 192 clinicopathologically characterized tumors.
    Gaffey TA, Scheithauer BW, Leech RW, Blick K, Kovacs K, Horvath E, Weaver AL, Lloyd RV, Ebersold M, Laws ER, DeBault LE.
    Clin Neuropathol; 2005 Dec; 24(2):56-63. PubMed ID: 15803804
    [Abstract] [Full Text] [Related]

  • 13. Multimodality treatment for invasive pituitary adenomas.
    Hornyak M, Couldwell WT.
    Postgrad Med; 2009 Mar; 121(2):168-76. PubMed ID: 19332975
    [Abstract] [Full Text] [Related]

  • 14. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L, Sánchez-Ortiga R, Moreno-Pérez O, Montañana CF, Niveiro M, Tritos NA, Alfonso AM.
    Endocrinol Nutr; 2013 Mar; 60(7):358-67. PubMed ID: 23416216
    [Abstract] [Full Text] [Related]

  • 15. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
    Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A.
    Neuroendocrinology; 2015 Mar; 101(2):143-50. PubMed ID: 25633744
    [Abstract] [Full Text] [Related]

  • 16. Pathobiology of pituitary adenomas and carcinomas.
    Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF, Meyer FB, Kuroki T, Riehle DL, Laws ER.
    Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
    [Abstract] [Full Text] [Related]

  • 17. CD147 expression in pituitary adenomas and its significance for clinical outcome.
    Qu X, Yang W, Jiang M, Han T, Han L, Qu Y, Wang G, Shi D, Xu G.
    Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
    [Abstract] [Full Text] [Related]

  • 18. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
    Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Vergès B, Chabre O, Calender A, Groupe d'études des Tumeurs Endocrines.
    Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
    [Abstract] [Full Text] [Related]

  • 19. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma.
    Zhang Y, He N, Zhou J, Chen Y.
    Clin Imaging; 2011 Apr; 35(3):165-73. PubMed ID: 21513851
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical analysis of RCAS1 in human pituitary adenomas.
    Umeoka K, Sanno N, Oyama K, Tahara S, Kurotani R, Ikuyama S, Nakashima M, Watanabe T, Osamura RY, Teramoto A.
    Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.